Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies.

Aliabadi HM, Bahadur K C R, Bousoik E, Hall R, Barbarino A, Thapa B, Coyle M, Mahdipoor P, Uludağ H.

Acta Biomater. 2020 Jan 15;102:351-366. doi: 10.1016/j.actbio.2019.11.036. Epub 2019 Nov 21.

PMID:
31760224
2.

Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs.

Bousoik E, Nabiee R, Amirrad F, Nichols A, Witt R, Mahdipoor P, Montazeri Aliabadi H.

Front Oncol. 2019 Oct 15;9:1070. doi: 10.3389/fonc.2019.01070. eCollection 2019.

3.

Amphiphilic Peptides for Efficient siRNA Delivery.

Mozaffari S, Bousoik E, Amirrad F, Lamboy R, Coyle M, Hall R, Alasmari A, Mahdipoor P, Parang K, Montazeri Aliabadi H.

Polymers (Basel). 2019 Apr 17;11(4). pii: E703. doi: 10.3390/polym11040703.

4.

In vitro and ex-vivo evaluation of topical formulations designed to minimize transdermal absorption of Vitamin K1.

Nabiee R, Dubois B, Green L, Sharma A, Wong SF, Montazeri Aliabadi H.

PLoS One. 2018 Oct 5;13(10):e0204531. doi: 10.1371/journal.pone.0204531. eCollection 2018.

5.

"Do We Know Jack" About JAK? A Closer Look at JAK/STAT Signaling Pathway.

Bousoik E, Montazeri Aliabadi H.

Front Oncol. 2018 Jul 31;8:287. doi: 10.3389/fonc.2018.00287. eCollection 2018. Review.

6.

Difatty Acyl-Conjugated Linear and Cyclic Peptides for siRNA Delivery.

Do H, Sharma M, El-Sayed NS, Mahdipoor P, Bousoik E, Parang K, Montazeri Aliabadi H.

ACS Omega. 2017 Oct 31;2(10):6939-6957. doi: 10.1021/acsomega.7b00741. Epub 2017 Oct 19.

7.

Synthesis, characterization, and in vitro cytotoxicity of fatty acyl-CGKRK-chitosan oligosaccharides conjugates for siRNA delivery.

El-Sayed NS, Sharma M, Aliabadi HM, El-Meligy MG, El-Zaity AK, Nageib ZA, Tiwari RK.

Int J Biol Macromol. 2018 Jun;112:694-702. doi: 10.1016/j.ijbiomac.2018.01.213. Epub 2018 Feb 2.

8.

Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research.

Al-Lawati H, Aliabadi HM, Makhmalzadeh BS, Lavasanifar A.

Expert Opin Drug Deliv. 2018 Apr;15(4):397-418. doi: 10.1080/17425247.2018.1420053. Epub 2018 Jan 1. Review.

9.

Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.

Parmar MB, Meenakshi Sundaram DN, K C RB, Maranchuk R, Montazeri Aliabadi H, Hugh JC, Löbenberg R, Uludağ H.

Acta Biomater. 2018 Jan 15;66:294-309. doi: 10.1016/j.actbio.2017.11.036. Epub 2017 Nov 26.

10.

Tumor-targeted delivery of siRNA using fatty acyl-CGKRK peptide conjugates.

Sharma M, El-Sayed NS, Do H, Parang K, Tiwari RK, Aliabadi HM.

Sci Rep. 2017 Jul 21;7(1):6093. doi: 10.1038/s41598-017-06381-y.

11.

Alzheimer's Disease: Dawn of a New Era?

Amirrad F, Bousoik E, Shamloo K, Al-Shiyab H, Nguyen VV, Montazeri Aliabadi H.

J Pharm Pharm Sci. 2017;20(0):184-225. doi: 10.18433/J3VS8P. Review.

12.

Single and Combinational siRNA Therapy of Cancer Cells: Probing Changes in Targeted and Nontargeted Mediators after siRNA Treatment.

Aliabadi HM, Mahdipoor P, Bisoffi M, Hugh JC, Uludağ H.

Mol Pharm. 2016 Dec 5;13(12):4116-4128. Epub 2016 Nov 15.

PMID:
27802596
13.

Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells.

Parmar MB, Arteaga Ballesteros BE, Fu T, K C RB, Montazeri Aliabadi H, Hugh JC, Löbenberg R, Uludağ H.

J Biomed Mater Res A. 2016 Dec;104(12):3031-3044. doi: 10.1002/jbm.a.35846. Epub 2016 Aug 9.

PMID:
27465922
14.

Identification of Potential Drug Targets in Cancer Signaling Pathways using Stochastic Logical Models.

Zhu P, Aliabadi HM, Uludağ H, Han J.

Sci Rep. 2016 Mar 18;6:23078. doi: 10.1038/srep23078.

15.

Application of iChip to Grow "Uncultivable" Microorganisms and its Impact on Antibiotic Discovery.

Sherpa RT, Reese CJ, Montazeri Aliabadi H.

J Pharm Pharm Sci. 2015;18(3):303-15. Review.

16.

Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.

Aliabadi HM, Mahdipoor P, Kucharsky C, Chan N, Uludağ H.

Pharm Res. 2015 Dec;32(12):3813-26. doi: 10.1007/s11095-015-1741-z. Epub 2015 Jul 1.

17.

Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines.

Parmar MB, Aliabadi HM, Mahdipoor P, Kucharski C, Maranchuk R, Hugh JC, Uludağ H.

Front Bioeng Biotechnol. 2015 Feb 16;3:14. doi: 10.3389/fbioe.2015.00014. eCollection 2015.

18.

Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.

Falamarzian A, Aliabadi HM, Molavi O, Seubert JM, Lai R, Uludağ H, Lavasanifar A.

J Biomed Mater Res A. 2014 Sep;102(9):3216-28. doi: 10.1002/jbm.a.34992. Epub 2013 Oct 25.

PMID:
24167124
19.

Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy.

Aliabadi HM, Maranchuk R, Kucharski C, Mahdipoor P, Hugh J, Uludağ H.

J Control Release. 2013 Nov 28;172(1):219-228. doi: 10.1016/j.jconrel.2013.08.012. Epub 2013 Aug 30.

PMID:
23994345
20.

Gelatin coating to stabilize the transfection ability of nucleic acid polyplexes.

Rose L, Aliabadi HM, Uludağ H.

Acta Biomater. 2013 Jul;9(7):7429-38. doi: 10.1016/j.actbio.2013.03.029. Epub 2013 Mar 27.

PMID:
23542234

Supplemental Content

Loading ...
Support Center